Posted in | News | Nanomedicine | Nanobusiness

RainDance Technologies Receives First European Order for Sequence Enrichment Solution

RainDance Technologies, Inc., a provider of innovative microdroplet-based solutions for human health and disease research, today announced it has received the first European order for its Sequence Enrichment Solution from ATLAS Biolabs GmbH of Berlin, Germany, a leading genomic services provider.

In an announcement at the European Society of Human Genetics (ESHG) Conference 2009, the company said ATLAS Biolabs’ purchase includes the RDT 1000 system, PCR primer libraries, consumables kits, and training services.

“ATLAS Biolabs is a renowned genomic services provider with an esteemed scientific team that is highly respected in the European research community,” said Christopher McNary, President and Chief Executive Officer, RainDance Technologies. “We look forward to supporting their requirements with a solution that can dramatically enhance their genomic research services portfolio.”

McNary said the sale represents a key addition to the company’s global service provider network. “With our Sequence Enrichment Solution in place at ATLAS Biolabs, European researchers will have immediate access to our technology. It will enable scientists to perform high-resolution analysis of genetic variation between individuals within populations at a level unmatched by current methodologies,” he said.

“Our customers now are exploring the contribution of rare variants in their study of disease and are adopting targeted genomic sequencing methods to study large populations in this context. RainDance’s massively parallel microdroplet PCR-based solution for sequence enrichment is superior to all others available in the market because it is less prone to the selection bias associated with targeted sequencing,” said Dr. Peter Nürnberg, Co-Founder and Chief Executive Officer, ATLAS Biolabs. “Using the RainDance technology, we can amplify up to 4000 amplicons in a single PCR process with essentially no allelic amplification bias and a near 100% success rate of PCR primer pairs.”

Nürnberg said ATLAS Biolabs is discussing the RainDance Sequence Enrichment Solution with key customers and will invite them to perform proof-of-principle experiments once the instrument is installed. “We are pleased to be the first in Europe to offer this innovative approach and will work with RainDance to explore additional applications for their promising new technology.”

RainDance will immediately begin designing custom DNA primer libraries for ATLAS Biolabs’ customers and anticipates shipping the RDT 1000 system by July 2009.

“The first sale of our Sequence Enrichment Solution in Europe is a major step in our company’s growth,” said McNary. “Our technology is generating considerable interest in the region, and we anticipate announcing additional sales to leading European genomic and medical research centers in the coming weeks.”

For sales information, contact Patrick Kelly, Director of Sales – European Region, RainDance Technologies, at [email protected] or +44-786-3200-242.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    RainDance Technologies, Inc.. (2019, February 14). RainDance Technologies Receives First European Order for Sequence Enrichment Solution. AZoNano. Retrieved on April 16, 2024 from https://www.azonano.com/news.aspx?newsID=11683.

  • MLA

    RainDance Technologies, Inc.. "RainDance Technologies Receives First European Order for Sequence Enrichment Solution". AZoNano. 16 April 2024. <https://www.azonano.com/news.aspx?newsID=11683>.

  • Chicago

    RainDance Technologies, Inc.. "RainDance Technologies Receives First European Order for Sequence Enrichment Solution". AZoNano. https://www.azonano.com/news.aspx?newsID=11683. (accessed April 16, 2024).

  • Harvard

    RainDance Technologies, Inc.. 2019. RainDance Technologies Receives First European Order for Sequence Enrichment Solution. AZoNano, viewed 16 April 2024, https://www.azonano.com/news.aspx?newsID=11683.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.